Efficacy Of Pathadya Churna In The Management Of Grahani D3osha

To Evaluate the Efficacy of Pathadya Churna in the Management of Grahani Dosha - A Clinical trial - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058300

Enrollment

100

Registered

2023-10-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 18-60 years 2. Patients having pratyatma lakshana of Grahanidosha especially – Atisrushtam or Ativibadhham or Atidravam malapravritti (altered bowel habits), Ama Mala Pravritti (Sticky stool) I. Durgandhita Mala Pravritti (Fowl Smelling stool) II. Pichchhila Mala Pravritti (Mucous mixed stool) Trushna, Arochaka, Vairasya, Praseka, Tamaka, Shoona pada kara, Asthi-parva ruka, Chardi, Jwara, Louha-ama-gandhi tiktamlodgar Udara Shoola (Abdominal pain) Udara Gaurava (Heaviness in abdomen) Atopa (Bloating) Able and willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Mixed infection with parasites such as round worms, hook worms etc. 2. Ulcerative colitis, Crohn’s disease, gastric ulcerations and other inflammatory bowel conditions. 3.Infectious disorders like Intestinal tuberculosis etc. 4. Patients with evidence of malignancy. 5. Patents with diabetes mellitus (FBS >126 mg/dl, PP >200 mg/dl), poorly controlled hypertension, Thyroid disorders and any other autoimmune disorders. 6. Amoebic dysentery, acute diarrhea. 7.Lactose intolerance patients. 8.Abuse of drug or alcohol. 9.Presence of other somatic or mental disorder requiring medication. 10.Patients on prolonged medication with NSAIDs, analgesics or any other drugs that may have an influence on the outcome of the study. 11.H/o hypersensitivity to any of the trial drugs or their ingredients. 12.Patients who have completed participation in any other clinical trial during the past 6 months which is interfering with the results of Grahani. 13.Patients with bleeding per rectum. 14. All the types of atisara, Antraja krimija patients and any other conditions interfering with the results of Grahani.

Design outcomes

Primary

Measure	Time frame
•Reduction in Signs & Symptoms by Correcting Agni & Ama. Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Improve the quality of life & wellbeing To evaluate the safety, sustainability & adverse drug reaction of trial drugTimepoint: 5 weeks	—

Countries

India

Contacts

Public ContactDr Kirti Rahul

Post Graduate Institute of Ayuveda Jodhpur

bkmudgal9@gmail.com7976964483

Outcome results